ADAP News and Press, Adaptimmune Therapeutics plc From 02/25/21

Adaptimmune Therapeutics PLC (ADAP) Q4 2020 Earnings Conference Call February 25, 2020 08:00 AM ET Company Participants Juli Miller - Senior Director, IR Adrian Rawcliffe - CEO Elliot Norry - Senior VP and Chief Medical Officer Helen Tayton-Martin - Co-Founder and Chief Business Officer Confe...

- Outlined strategy to build integrated cell therapy company and the Company’s “2-2-5-2” five-year core value drivers - - Reported compelling durable responses in patients with synovial sarcoma, and initial responses in lung, head and neck, liver, esophagogastric ju...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the fourth quarter and year ended December 31, 2020, before th...

Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound. If successful, this could be a killer investment. If not, you will lose your entire money. For further details see: Ad...

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma - - Next registration directed trial initiating with ADP-A2M4CD8 in 1H 2021 for patients with gastroesophageal cancers - - Efficacy with SPEAR T-cells in multiple solid...

- Data support confidence in SPEARHEAD-1 as a registrational trial - - Projected to complete recruitment of all patients in Q1 2021 - - Median duration of response was 28 weeks with ongoing responses beyond 72 weeks in two patients; median overall survival has not been r...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Investor Day on November 20, 2020 at 8AM EST/ 1PM GMT. A lin...

The following slide deck was published by Adaptimmune Therapeutics plc in conjunction with this event. For further details see: Adaptimmune Therapeutics (ADAP) Presents At SITC Virtual Annual Meeting 2020 - Slideshow

Beyond Meat (BYND) -23% on Q3 earnings release.InnSuites Hospitality (IHT) -20%.Jumia Technologies (JMIA) -19% on Q3 earnings release.Aurora Cannabis (ACB) -13%.Applied UV (AUVI) -13%.GasLog Partners (GLOP) -13% on Q3 earnings release.Waitr Holdings (WTRH) -...

- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell t...